Skip Navigation
Print This Page
Share this page: More

Search Results

G9927 A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and Veliparib (ABT-888) and Bevacizumab in Recurrent Platinum-Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Protocol Number:
Phase I
Deborah Armstrong
- To determine the maximum tolerated doses and dose-limiting toxicities of two different regimens of ABT-888 when administered with carboplatin and PLD (Doxil®, Lipodox�) in recurrent, platinum sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancer. - To estimate the objective response rate (complete and partial) in patients with measureable disease.
- platinum sensitive recurrent ovarian cancer - may have an unlimited number of platinum based therapies - may only have one non-platinum therapy in recurrent setting - no prior PARP inhibitors - no prior anti-angiogenic (ie bevacizumab) in recurrent setting - may have measurable disease, detectable disease or biochemical recurrence(elevated CA-125 - good lab values, performace status and organ function
This is an outpatient regimen consisting of two regimens. Both groups will receive IV PLD and IV Carboplatin every 28 days. Both groups will receive ABT-888 orally either on Days 1-7 or Days 1-28 in alternating groups.
Last Update
04/17/2014 04:02 AM

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers


Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424



© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer